|
Age, yr
| |
|
Mean (SD)
|
41.4 (13.7)
|
|
Median (range)
|
39.2 (18–76)
|
|
Female sex, n (%)
|
63 (91.3)
|
|
Disease duration, yr, median (range)
|
7.5 (0–41)
|
|
Follow-up duration, d, median (range)
|
778 (139–1792)
|
|
Corticosteroid treatment, n (%)
|
33 (47.8)
|
|
Prednisolone equivalent, average dose last 2 mo, median (range)
|
10 (1–60) mg/d
|
|
Antimalarial treatment
|
46 (66.7)
|
|
Hydroxychloroquine, average dose last 2 mo, median (range)
|
200 (46.6–400) mg/d
|
|
Immunomodulatory treatment, n (%)
|
37 (53.6)
|
|
ACR classification criteria n (%)
| |
|
Malar rash
|
46 (67 %)
|
|
Discoid rash
|
18 (26 %)
|
|
Photosensitivity
|
42 (61 %)
|
|
Oral ulcer
|
16 (23 %)
|
|
Arthritis
|
55 (80 %)
|
|
Serositis
|
35 (51 %)
|
|
Glomerulonephritis
|
35 (51 %)
|
|
Hematologic disorder
|
38 (55 %)
|
|
Neurologic disorder
|
3 (4 %)
|
|
Immunologic disorder
|
53 (77 %)
|
|
ANA positivity
|
69 (100 %)
|
|
Outcome of PNC assay, % CD66+PI+ PMNs
| |
|
Mean (SD)
|
7.3 (9.0)
|
|
Median (range)
|
3.4 (0.8–49.9)
|
